These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 37451499)

  • 21. Five-Year Clinical Outcomes of Intravitreal Bevacizumab Versus Laser Photocoagulation for ROP.
    Moinul P; Nanji K; Barbosa J; Sarohia GS; Fung M; Isaza G; Chaudhary V
    J Pediatr Ophthalmol Strabismus; 2024; 61(1):73-74. PubMed ID: 38306241
    [No Abstract]   [Full Text] [Related]  

  • 22. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
    Sankar MJ; Sankar J; Mehta M; Bhat V; Srinivasan R
    Cochrane Database Syst Rev; 2016; 2():CD009734. PubMed ID: 26932750
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Effects of intravitreal pegaptanib or bevacizumab and laser in treatment of threshold retinopathy of prematurity in zone I and posterior zone II--four years results].
    Autrata R; Senková K; Holousová M; Krejcírová I; Dolezel Z; Borek I
    Cesk Slov Oftalmol; 2012 Feb; 68(1):29-36. PubMed ID: 22679695
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Short-term retinal detachment risk after treatment of type 1 retinopathy of prematurity with laser photocoagulation versus intravitreal bevacizumab.
    Barry GP; Tauber KA; Fisher M; Greenberg S; Zobal-Ratner J; Binenbaum G
    J AAPOS; 2019 Oct; 23(5):260.e1-260.e4. PubMed ID: 31513902
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low- and Very Low-Dose Bevacizumab for Retinopathy of Prematurity: Reactivations, Additional Treatments, and 12-Month Outcomes.
    Freedman SF; Hercinovic A; Wallace DK; Kraker RT; Li Z; Bhatt AR; Boente CS; Crouch ER; Hubbard GB; Rogers DL; VanderVeen D; Yang MB; Cheung NL; Cotter SA; Holmes JM;
    Ophthalmology; 2022 Oct; 129(10):1120-1128. PubMed ID: 35660415
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of supplemental oxygen in reducing the need for laser or intravitreal bevacizumab in preterm infants with stage 2 retinopathy of prematurity.
    Minturn R; Hartigan K; Vegunta S; Boente C; Golzarri-Arroyo L; Hynes E; Laughlin E; Haider K; Kua KL
    BMC Ophthalmol; 2024 May; 24(1):220. PubMed ID: 38790043
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined intravitreal bevacizumab injection and zone I sparing laser photocoagulation in patients with zone I retinopathy of prematurity.
    Kim J; Kim SJ; Chang YS; Park WS
    Retina; 2014 Jan; 34(1):77-82. PubMed ID: 23807184
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Atypical case of retinopathy of prematurity with candle wax-like preretinal deposits and its surprising response to intravitreal antivascular endothelial growth factor.
    Shah MS; Padhy SK; Sahu S; Padhi TR
    BMJ Case Rep; 2022 Jan; 15(1):. PubMed ID: 35039342
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of the Efficacy Between Intravitreal Aflibercept and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity.
    Ekinci DY; Çelik K
    J Pediatr Ophthalmol Strabismus; 2020 Jan; 57(1):54-60. PubMed ID: 31972042
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of 5-year safety and efficacy of laser photocoagulation and intravitreal bevacizumab injection in retinopathy of prematurity.
    Murakami T; Sugiura Y; Okamoto F; Okamoto Y; Kato A; Hoshi S; Nagafuji M; Miyazono Y; Oshika T
    Graefes Arch Clin Exp Ophthalmol; 2021 Sep; 259(9):2849-2855. PubMed ID: 33744981
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chronic Vascular Arrest as a Predictor of Bevacizumab Treatment Failure in Retinopathy of Prematurity.
    Toy BC; Schachar IH; Tan GS; Moshfeghi DM
    Ophthalmology; 2016 Oct; 123(10):2166-75. PubMed ID: 27506484
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective Analysis.
    Hwang CK; Hubbard GB; Hutchinson AK; Lambert SR
    Ophthalmology; 2015 May; 122(5):1008-15. PubMed ID: 25687024
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity.
    Chung EJ; Kim JH; Ahn HS; Koh HJ
    Graefes Arch Clin Exp Ophthalmol; 2007 Nov; 245(11):1727-30. PubMed ID: 17690897
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low dose versus conventional dose of intravitreal bevacizumab injection for retinopathy of prematurity: a case series with paired-eye comparison.
    Han J; Kim SE; Lee SC; Lee CS
    Acta Ophthalmol; 2018 Jun; 96(4):e475-e478. PubMed ID: 27011262
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fluorescein angiographic features post-intravitreal bevacizumab for retinopathy of prematurity: can they support rescue laser photocoagulation to the avascular retina.
    Gonzalez A; Agarwal-Sinha S
    Can J Ophthalmol; 2020 Oct; 55(5):373-381. PubMed ID: 32835673
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Spectrum of Regression Following Intravitreal Bevacizumab in Retinopathy of Prematurity.
    Chen TA; Shields RA; Bodnar ZH; Callaway NF; Schachar IH; Moshfeghi DM
    Am J Ophthalmol; 2019 Feb; 198():63-69. PubMed ID: 30312578
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity - 27 month follow-up results from Turkey.
    Yetik H; Gunay M; Sirop S; Salihoglu Z
    Graefes Arch Clin Exp Ophthalmol; 2015 Oct; 253(10):1677-83. PubMed ID: 25501298
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of anti-vascular endothelial growth factor in treatment of retinopathy of prematurity-a current review.
    Chow SC; Lam PY; Lam WC; Fung NSK
    Eye (Lond); 2022 Aug; 36(8):1532-1545. PubMed ID: 35017699
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of intravitreal bevacizumab for the treatment of retinopathy of prematurity: a single-center retrospective review.
    Frosini S; Franco F; Vicini G; Nicolosi C; Varriale G; Dani C; Virgili G; Giansanti F
    J Matern Fetal Neonatal Med; 2022 Sep; 35(17):3337-3342. PubMed ID: 32933350
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A lower dose of intravitreal bevacizumab effectively treats retinopathy of prematurity.
    Khodabande A; Niyousha MR; Roohipoor R
    J AAPOS; 2016 Dec; 20(6):490-492. PubMed ID: 27794470
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.